FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380730227> ?p ?o ?g. }

• W4380730227 endingPage "900" @default.
• W4380730227 startingPage "894" @default.
• W4380730227 abstract "Abstract Background Non-clear cell renal cell carcinoma (nccRCC) is a blanket term for a collection of heterogeneous and biologically diverse RCC histologies, including but not limited to papillary, chromophobe, and unclassified subtypes. Tivozanib is a selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) that demonstrated activity in RCC with clear cell component. The objective of this analysis was to determine the efficacy of tivozanib in histologically unclassified/mixed RCC. Methods We identified patients with nccRCC enrolled in Study 201 (NCT00502307) between October 2007 and July 2008. This was a phase II randomized discontinuation trial of tivozanib in patients with RCC who had no prior VEGFR-targeted treatment. Clinical outcomes including investigator-assessed objective response rate (ORR), disease control rate (DCR, defined by complete response + partial response + stable disease), and progression-free survival (PFS) were examined. Results Of the 272 patients enrolled, 46 (16.9%) patients had nccRCC: 11 (4%) papillary, 2 (0.7%) chromophobe, 2 (0.7%) collecting duct, and 31 (11.4%) mixed/unclassified. Of the 46 patients with nccRCC, 38 were continuously treated with tivozanib and the best ORR was 21.1% (confirmed) and 31.6% (confirmed and unconfirmed). The DCR was 73.7% and median PFS was 6.7 months (95% confidence interval, 125-366 days). There were no new safety signals compared to the ITT population. Limitations include the small number of individual nccRCC subtypes and the randomized discontinuation design. Conclusion Tivozanib demonstrated activity and a favorable safety profile in patients with nccRCC. These data add to the body of evidence supporting the use of VEGFR-TKI in advanced nccRCC." @default.
• W4380730227 created "2023-06-16" @default.
• W4380730227 creator A5002681805 @default.
• W4380730227 creator A5015358832 @default.
• W4380730227 creator A5041033274 @default.
• W4380730227 creator A5044516598 @default.
• W4380730227 creator A5053588971 @default.
• W4380730227 creator A5089963162 @default.
• W4380730227 date "2023-06-14" @default.
• W4380730227 modified "2023-10-07" @default.
• W4380730227 title "Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial" @default.
• W4380730227 cites W1972885091 @default.
• W4380730227 cites W2015644147 @default.
• W4380730227 cites W2059499441 @default.
• W4380730227 cites W2141444851 @default.
• W4380730227 cites W2143782771 @default.
• W4380730227 cites W2167093073 @default.
• W4380730227 cites W2173523195 @default.
• W4380730227 cites W2233483325 @default.
• W4380730227 cites W2284518822 @default.
• W4380730227 cites W2614480329 @default.
• W4380730227 cites W2618845284 @default.
• W4380730227 cites W2770458551 @default.
• W4380730227 cites W2792937256 @default.
• W4380730227 cites W2898370664 @default.
• W4380730227 cites W2916100539 @default.
• W4380730227 cites W2946936611 @default.
• W4380730227 cites W2980301532 @default.
• W4380730227 cites W2991986029 @default.
• W4380730227 cites W3010596500 @default.
• W4380730227 cites W3030472743 @default.
• W4380730227 cites W3085486789 @default.
• W4380730227 cites W3089329253 @default.
• W4380730227 cites W3129780093 @default.
• W4380730227 cites W3131063362 @default.
• W4380730227 cites W3134949580 @default.
• W4380730227 cites W3159514559 @default.
• W4380730227 cites W4220751448 @default.
• W4380730227 cites W4220876289 @default.
• W4380730227 cites W4226082711 @default.
• W4380730227 cites W4237816489 @default.
• W4380730227 cites W4292822476 @default.
• W4380730227 cites W4361866993 @default.
• W4380730227 doi "https://doi.org/10.1093/oncolo/oyad132" @default.
• W4380730227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37315114" @default.
• W4380730227 hasPublicationYear "2023" @default.
• W4380730227 type Work @default.
• W4380730227 citedByCount "0" @default.
• W4380730227 crossrefType "journal-article" @default.
• W4380730227 hasAuthorship W4380730227A5002681805 @default.
• W4380730227 hasAuthorship W4380730227A5015358832 @default.
• W4380730227 hasAuthorship W4380730227A5041033274 @default.
• W4380730227 hasAuthorship W4380730227A5044516598 @default.
• W4380730227 hasAuthorship W4380730227A5053588971 @default.
• W4380730227 hasAuthorship W4380730227A5089963162 @default.
• W4380730227 hasBestOaLocation W43807302271 @default.
• W4380730227 hasConcept C126322002 @default.
• W4380730227 hasConcept C126894567 @default.
• W4380730227 hasConcept C143998085 @default.
• W4380730227 hasConcept C168563851 @default.
• W4380730227 hasConcept C187960798 @default.
• W4380730227 hasConcept C2777472916 @default.
• W4380730227 hasConcept C2778560582 @default.
• W4380730227 hasConcept C2778715236 @default.
• W4380730227 hasConcept C2781278892 @default.
• W4380730227 hasConcept C2908647359 @default.
• W4380730227 hasConcept C31760486 @default.
• W4380730227 hasConcept C44249647 @default.
• W4380730227 hasConcept C535046627 @default.
• W4380730227 hasConcept C71924100 @default.
• W4380730227 hasConcept C78795084 @default.
• W4380730227 hasConcept C90924648 @default.
• W4380730227 hasConcept C99454951 @default.
• W4380730227 hasConceptScore W4380730227C126322002 @default.
• W4380730227 hasConceptScore W4380730227C126894567 @default.
• W4380730227 hasConceptScore W4380730227C143998085 @default.
• W4380730227 hasConceptScore W4380730227C168563851 @default.
• W4380730227 hasConceptScore W4380730227C187960798 @default.
• W4380730227 hasConceptScore W4380730227C2777472916 @default.
• W4380730227 hasConceptScore W4380730227C2778560582 @default.
• W4380730227 hasConceptScore W4380730227C2778715236 @default.
• W4380730227 hasConceptScore W4380730227C2781278892 @default.
• W4380730227 hasConceptScore W4380730227C2908647359 @default.
• W4380730227 hasConceptScore W4380730227C31760486 @default.
• W4380730227 hasConceptScore W4380730227C44249647 @default.
• W4380730227 hasConceptScore W4380730227C535046627 @default.
• W4380730227 hasConceptScore W4380730227C71924100 @default.
• W4380730227 hasConceptScore W4380730227C78795084 @default.
• W4380730227 hasConceptScore W4380730227C90924648 @default.
• W4380730227 hasConceptScore W4380730227C99454951 @default.
• W4380730227 hasIssue "10" @default.
• W4380730227 hasLocation W43807302271 @default.
• W4380730227 hasLocation W43807302272 @default.
• W4380730227 hasOpenAccess W4380730227 @default.
• W4380730227 hasPrimaryLocation W43807302271 @default.
• W4380730227 hasRelatedWork W1527054091 @default.
• W4380730227 hasRelatedWork W2070002316 @default.
• W4380730227 hasRelatedWork W2086578727 @default.

• next